BridgeBio Pharma PE Ratio 2018-2026 | BBIO
Current and historical p/e ratio for BridgeBio Pharma (BBIO) from 2018 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. BridgeBio Pharma PE ratio as of May 20, 2026 is 0.00.
| BridgeBio Pharma PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-05-20 | 68.22 | 0.00 | |
| 2026-03-31 | 74.26 | $-3.74 | 0.00 |
| 2025-12-31 | 76.49 | $-3.78 | 0.00 |
| 2025-09-30 | 51.94 | $-4.21 | 0.00 |
| 2025-06-30 | 43.18 | $-4.12 | 0.00 |
| 2025-03-31 | 34.57 | $-3.56 | 0.00 |
| 2024-12-31 | 27.44 | $-2.88 | 0.00 |
| 2024-09-30 | 25.46 | $-2.42 | 0.00 |
| 2024-06-30 | 25.33 | $-2.64 | 0.00 |
| 2024-03-31 | 30.92 | $-3.23 | 0.00 |
| 2023-12-31 | 40.37 | $-3.95 | 0.00 |
| 2023-09-30 | 26.37 | $-3.89 | 0.00 |
| 2023-06-30 | 17.20 | $-3.74 | 0.00 |
| 2023-03-31 | 16.58 | $-2.83 | 0.00 |
| 2022-12-31 | 7.62 | $-3.26 | 0.00 |
| 2022-09-30 | 9.94 | $-3.35 | 0.00 |
| 2022-06-30 | 9.08 | $-3.48 | 0.00 |
| 2022-03-31 | 10.15 | $-4.07 | 0.00 |
| 2021-12-31 | 16.68 | $-3.90 | 0.00 |
| 2021-09-30 | 46.87 | $-3.91 | 0.00 |
| 2021-06-30 | 60.96 | $-3.83 | 0.00 |
| 2021-03-31 | 61.60 | $-4.20 | 0.00 |
| 2020-12-31 | 71.11 | $-3.80 | 0.00 |
| 2020-09-30 | 37.52 | $-3.39 | 0.00 |
| 2020-06-30 | 32.61 | $-2.92 | 0.00 |
| 2020-03-31 | 29.00 | $-2.60 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |